We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novavax Finishes Enrollment for U.S. Phase 3 COVID-19 Vaccine Trial
Novavax Finishes Enrollment for U.S. Phase 3 COVID-19 Vaccine Trial
Novavax has announced that it has completed enrolling 30,000 participants in its late-stage U.S./Mexico pivotal trial of its COVID-19 vaccine, bringing its recombinant protein-based vaccine hopeful one step closer to potential FDA authorization.